Eton Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and Marketing
May 04, 2020 08:00 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., May 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
March 27, 2020 07:00 ET
|
Eton Pharmaceuticals
-Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date -Alkindi Sprinkle has been Granted Orphan...
Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)
March 17, 2020 08:00 ET
|
Eton Pharmaceuticals
-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Greater than $800 million Annually DEER PARK, Ill., March ...
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
March 05, 2020 16:02 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., March 05, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
February 27, 2020 16:10 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals Provides Update on ET-105 Program
February 19, 2020 08:00 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference
February 13, 2020 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement
January 21, 2020 07:00 ET
|
Eton Pharmaceuticals
Xellia’s US-based Hospital Sales Force Will Immediately Begin Promoting Biorphen in Collaboration with EtonAgreement Significantly Expands Biorphen Commercial Footprint and Provides Access to...
Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection
December 02, 2019 07:30 ET
|
Eton Pharmaceuticals
~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen is Now Available for Order Through Major Wholesalers ~ ~ Biorphen is Eton...
Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress
November 14, 2019 16:01 ET
|
Eton Pharmaceuticals
Biorphen® Expected to Launch by End of NovemberCompany to Host Conference Call and Webcast Today at 4:30 p.m. ET (3:30 p.m. CT) DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton...